SecBot SecBot
6-K ·Filed Nov 3, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 5/10
Horizonmonths Processed13d 12h ago SEC0001776985-26-000080
6-K: Earnings release
Actionable Insight • Neutral

Revenue beat consensus and guidance midpoint raised, but the underlying trend is declining COVID-19 vaccine revenue as the company transitions to oncology. Key catalysts to watch: the first interim analysis of the gotistobart Phase 3 PRESERVE-003 trial expected in 2026, and the OS readout from the BNT113 AHEAD-MERIT trial. The trastuzumab pamirtecan BLA submission timeline remains under discussion.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

BNTX drug pipeline →

gotistobart

● Neutral Named in this 6-K
Impact
Phase
Phase 3
Time to market
At least 2-4 years away from potential approval, assuming positive Phase 3 data leads to regulatory filing. The PRESERVE-003 Phase 3 trial is ongoing with updated OS data due Sept 2026, but no regulatory submission has been announced.
Next catalyst
None dated

What to watchThe key near-term catalyst is the WCLC 2026 conference (Sept 12-15, 2026), where updated overall survival data from the Phase 3 PRESERVE-003 trial of gotistobart in squamous NSCLC will be presented. Positive data could drive BNTX shares higher, but gotistobart is one of several late-stage assets in BioNTech's broad pipeline, so the stock impact is unlikely to be binary.

Price Chart

Loading chart...

Executive Summary

BioNTech reported Q3 2026 revenue of 1,289.2 million (down 15% YoY from 1,518.9 million) and IFRS net profit of 184.5 million vs a loss of 28.7 million a year ago. The company raised the midpoint of its full-year 2026 revenue guidance to 1.7-1.9 billion from 1.6-1.9 billion, citing Q3 performance. Revenue also exceeded the 1.04 billion consensus. However, year-to-date revenues declined 23% and the company remains in an IFRS net loss position year-to-date, reflecting declining COVID-19 vaccine demand offset by growing pipeline investments.

Key Financial Metrics

EPS (Adj.)
$1.76
GAAP: $0.73
Revenue
$1.3B
est $1.0B · +24.0% · -15.1% YoY
Guidance
1.7-1.9 billion
raised

Key Facts

  • Q3 2026 IFRS revenue 1,289.2 million vs 1,518.9 million in Q3 2025 (down 15.1% YoY)
  • Q3 2026 IFRS net profit 184.5 million vs net loss of 28.7 million in Q3 2025
  • Q3 2026 adjusted diluted EPS 1.76 vs adjusted diluted EPS 3.11 in Q3 2025
  • Raised full-year 2026 revenue guidance midpoint to 1.7-1.9 billion from 1.6-1.9 billion
  • Cash, cash equivalents and security investments of 16.2 billion as of September 30, 2026
  • Share repurchase program: 5,037,452 ADSs repurchased for 463.3 million through September 30, 2026
  • BNT113 Phase 2/3 trial in HNSCC did not meet PFS endpoint; trial continues for OS
  • Trastuzumab pamirtecan Phase 3 DYNASTY-Breast02 met PFS with modest improvement; higher ILD rate observed
  • Early termination initiated in Phase 2 trial of autogene cevumeran in adjuvant CRC

Financial Impact

Q3 revenue 1,289.2 million vs consensus 1.04 billion; adjusted diluted EPS 1.76 vs consensus 0.76 per ADS

revenueepsguidance

Risk Factors

  • Declining COVID-19 vaccine revenue as pandemic demand normalizes
  • BNT113 failed PFS endpoint; OS readout needed to determine trial outcome
  • Trastuzumab pamirtecan showed modest PFS benefit with higher ILD rate, potentially limiting commercial opportunity
  • Year-to-date IFRS net loss of 1,168.2 million driven by high R&D spending and restructuring costs
  • Autogene cevumeran Phase 2 CRC trial terminated early

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
69% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000080
Document: a992bntx3q2026presentati.htm0001776985-26-000080
Document: form6-kq32026earningsprear.htm0001776985-26-000080
Document: 0001776985-26-000080-index-headers.html0001776985-26-000080
Document: 0001776985-26-000080-index.html0001776985-26-000080
Document: 0001776985-26-000080.txt0001776985-26-000080
Earnings Context (Synthetic; results releases only)0001776985-26-000080

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.60 −1.85% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 Viewing No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.60 −1.52% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.60 −3.96% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.60 +1.45% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.60 −1.45% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.60 −4.54% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026